Innate Immunotherapeutics
Innate Immunotherapeutics Limited is a medical biotechnology company with offices in Sydney and Auckland.
The Company is currently conducting a Phase 2B efficacy trial of its drug candidate (MIS416) in patients with secondary progressive multiple sclerosis (SPMS). There are currently no safe and effective ongoing treatments for this progressive and highly disabling form of multiple sclerosis.
On completion of this study, expected 2017, the Company’s strategy is to partner this clinical programme application with ‘big pharma’ to complete approval trials and launch sales into the worldwide unmet market for SPMS.
Latest Media Releases
Latest News
Interviews /
by Carolyn Herbert -
7 years ago
21 November 2016 - Innate Immunotherapeutics (ASX:IIL) CEO, Simon Wilkinson, discusses the company’s microparticle technology and its lead drug candidate for secondary progressive …
Interviews /
by -
7 years ago
14 Apr 2016 - Innate Immunotherapeutics Limited (ASX:IIL) Managing Director, Simon Wilkinson discusses the company’s technology and lead drug candidate, MIS416.
Company News /
by -
9 years ago
11 Nov 2014 - Innate Immunotherapeutics Limited (ASX:IIL) commences patient dosing in its phase 2B trial of MIS416.
Market Reports /
by -
10 years ago
11 Mar 2014 -Aus shares flat on weak materials. Austal Limited (ASX:ASB) announces the inking of a contract for two more littoral combat vessels for the US Navy.